New drug combo tested to shield cancer patients from dangerous transplant side effect
NCT ID NCT06973668
Summary
This study aims to find the better drug combination for preventing graft-versus-host disease (GVHD), a serious complication, after a stem cell transplant for blood cancers like AML. Researchers will compare two different three-drug regimens in about 80 participants aged 65-75. The main goal is to see which combination is safer and more effective at preventing GVHD while still allowing the transplant to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.